Coldstream Capital Management
VYGR icon

Coldstream Capital Management’s Voyager Therapeutics VYGR Stock Holding History

Coldstream Capital Management’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,749
Closed -$46.2K – 1270
2025
Q4 		$46.2K Sell
11,749
-26
-0.2% -$115 ﹤0.01% 1150
2025
Q3 		$55K Buy
+11,775
New +$42.6K ﹤0.01% 1205

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Armistice Capital
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Erste Asset Management
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Coldstream Capital Management's VYGR Position: Q1 2026 in Review

Coldstream Capital Management sold out of Voyager Therapeutics (VYGR) in Q1 2026, closing a stake of 11,749 shares — an estimated $46.2K sold.

Coldstream Capital Management first reported a position in VYGR in Q3 2025 and held it in 2 quarters. The position peaked at $55K in Q3 2025. 135 funds tracked by Wall St. Rank hold VYGR as of Q1 2026.

  • Coldstream Capital Management reported no remaining Voyager Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Coldstream Capital Management sold 11,749 Voyager Therapeutics shares in Q1 2026, an estimated $46.2K.
  • Coldstream Capital Management first reported a position in Voyager Therapeutics in Q3 2025 and held it in 2 quarters.
  • Coldstream Capital Management's Voyager Therapeutics position peaked at $55K in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.